1. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia
- Author
-
Nina Malecic and Helen S. Young
- Subjects
Vascular Endothelial Growth Factor A ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Angiogenesis ,Population ,Ischemia ,Dermatology ,Biochemistry ,Pathogenesis ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,angiogenesis ,0302 clinical medicine ,cardiovascular disease ,Internal medicine ,Psoriasis ,medicine ,Animals ,Humans ,education ,Molecular Biology ,education.field_of_study ,Neovascularization, Pathologic ,vascular endothelial growth factor ,Manchester Cancer Research Centre ,business.industry ,ResearchInstitutes_Networks_Beacons/mcrc ,psoriasis ,Atherosclerosis ,medicine.disease ,Comorbidity ,Vascular endothelial growth factor ,030104 developmental biology ,chemistry ,Metabolic syndrome ,atherosclerosis ,business ,Signal Transduction - Abstract
Psoriasis, a common disease affecting 2%-3% of the UK population, produces significant impairment of quality of life and is an immense burden on sufferers and their families. Psoriasis is associated with significant cardiovascular comorbidity and the metabolic syndrome. Angiogenesis, a relatively under-researched component of psoriasis, is a key factor in pathogenesis of psoriasis and also contributes to the development of atherosclerosis. Vascular endothelial growth factor (VEGF) is a well-established mediator of pathological angiogenesis which is upregulated in psoriasis. It is possible that, in patients with psoriasis, cutaneous angiogenesis may be both a marker for systemic vascular pathology and a novel therapeutic target. In this viewpoint study, the role of VEGF-mediated angiogenesis as a cause for cardiovascular events in patients with psoriasis is explored.
- Published
- 2017
- Full Text
- View/download PDF